To directly examine
whether ABL kinases regulate tumor - induced osteoclast activation, we used an in vitro osteoclastogenesis assay (Fig. 5A).
To directly examine
whether ABL kinases play a role in regulating the colonization and survival of breast cancer cells in the bone microenvironment, we injected control or ABL1 / ABL2 knockdown breast cancer cells directly into the tibia of immunodeficient mice.
(A) Kaplan - Meier representation of the probability of cumulative overall disease - free survival in TCGA data set with 971 invasive breast cancer patients according to
whether the ABL signature (ABL2, TAZ, AXL, CTGF, STAT5A, STAT5B, TNC, IL6, and MMP1) was altered or not.
To evaluate
whether ABL kinases might regulate the secretion of osteoblast - derived RANKL or OPG leading to osteoclast differentiation, we analyzed RANKL and OPG mRNA abundance in the murine osteoblast cell line 7F2 in response to conditioned medium from control and ABL1 / ABL2 knockdown breast cancer cells.
AXL mediates resistance to TRAIL - induced cell death in esophageal adenocarcinoma (55); it remains to be determined
whether ABL - mediated protection from TRAIL - induced apoptosis in breast cancer cells is mediated by AXL or other targets.
However,
whether ABL kinases have a role in the regulation of cellular processes critical for metastasis, other than invasion, has not yet been evaluated.
Not exact matches
To test
whether the P210 is the product of the novel 8.5 - kilobase bcr /
abl fusion transcript, antibodies were prepared against c -
abl and bcr determinants.
ABL kinases regulate cancer cell invasion (21), but it is unclear
whether they play a role in the regulation of subsequent steps of the metastatic cascade.
To evaluate
whether the TAZ and STAT5 pathways promote breast cancer bone metastasis downstream of the
ABL kinases, we expressed the constitutively active mutants TAZ S89A and STAT5 * in
ABL1 /
ABL2 knockdown cells.
To evaluate
whether altered expression of the
ABL genes is associated with breast cancer progression and metastasis, we examined the expression of
ABL1 and
ABL2 in normal and invasive breast tumor specimens using published TCGA (The Cancer Genome Atlas) data sets (14 — 16).
To evaluate
whether loss of
ABL kinases affected TAZ activity, we performed chromatin immunoprecipitation (ChIP) analysis using primers for TAZ targets identified by ChIP sequencing analysis (42).
Thus, we evaluated
whether addition of IL - 6 could in part rescue defective osteoclastogenesis induced by conditioned medium from breast cancer cells depleted of the
ABL kinases.
Together, our data suggest that clinical studies may be warranted to evaluate the therapeutic potential of
ABL allosteric inhibitors and to determine
whether combination therapies that incorporate these compounds are effective in treating metastatic breast cancer.
Whether you're a new investor or have done multiple deals,
ABL has assembled a fix and flip guide for the state of Florida that breaks down investing in the sunshine state and ensures the right path forward.